Search Results - "Rukazenkov, Yuri"

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer by Wu, Yi-Long, Tsuboi, Masahiro, He, Jie, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W, Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu-Vinh, Lu, Shun, Lee, Kye-Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Zeng, Lingmin, Hodge, Rachel, Atasoy, Ajlan, Rukazenkov, Yuri, Herbst, Roy S

“…The incidence of recurrence after curative resection among patients with stage IB, II, or IIIA non–small-cell lung cancer is high and is only slightly lower…”
Get full text

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC by Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles

“…Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in EGFR . The median overall…”
Get full text

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer by Ramalingam, Suresh S, Yang, James C-H, Lee, Chee Khoon, Kurata, Takayasu, Kim, Dong-Wan, John, Thomas, Nogami, Naoyuki, Ohe, Yuichiro, Mann, Helen, Rukazenkov, Yuri, Ghiorghiu, Serban, Stetson, Daniel, Markovets, Aleksandra, Barrett, J Carl, Thress, Kenneth S, Jänne, Pasi A

“…Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety…”
Get full text

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study by Ellis, Matthew J, Llombart-Cussac, Antonio, Feltl, David, Dewar, John A, Jasiówka, Marek, Hewson, Nicola, Rukazenkov, Yuri, Robertson, John F R

“…To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer. The Fulvestrant…”
Get full text

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer by Chmielecki, Juliann, Gray, Jhanelle E., Cheng, Ying, Ohe, Yuichiro, Imamura, Fumio, Cho, Byoung Chul, Lin, Meng-Chih, Majem, Margarita, Shah, Riyaz, Rukazenkov, Yuri, Todd, Alexander, Markovets, Aleksandra, Barrett, J. Carl, Hartmaier, Ryan J., Ramalingam, Suresh S.

“…Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M…”
Get full text

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) by FUKUOKA, Masahiro, WU, Yi-Long, DUFFIELD, Emma L, RUKAZENKOV, Yuri, SPEAKE, Georgina, HAIYI JIANG, ARMOUR, Alison A, TO, Ka-Fai, CHIH-HSIN YANG, James, MOK, Tony S. K, THONGPRASERT, Sumitra, SUNPAWERAVONG, Patrapim, LEONG, Swan-Swan, SRIURANPONG, Virote, CHAO, Tsu-Yi, NAKAGAWA, Kazuhiko, CHU, Da-Tong, SAIJO, Nagahiro

“…The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light…”
Get full text

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection by Wu, Yi-Long, Herbst, Roy S., Mann, Helen, Rukazenkov, Yuri, Marotti, Marcelo, Tsuboi, Masahiro

“…Currently, the role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as adjuvant therapy for early-stage non–small-cell lung cancer after…”
Get full text

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer by Chmielecki, Juliann, Gray, Jhanelle E., Cheng, Ying, Ohe, Yuichiro, Imamura, Fumio, Cho, Byoung Chul, Lin, Meng-Chih, Majem, Margarita, Shah, Riyaz, Rukazenkov, Yuri, Todd, Alexander, Markovets, Aleksandra, Barrett, J. Carl, Hartmaier, Ryan J., Ramalingam, Suresh S.

Get full text

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer by Reungwetwattana, Thanyanan, Nakagawa, Kazuhiko, Cho, Byoung Chul, Cobo, Manuel, Cho, Eun Kyung, Bertolini, Alessandro, Bohnet, Sabine, Zhou, Caicun, Lee, Ki Hyeong, Nogami, Naoyuki, Okamoto, Isamu, Leighl, Natasha, Hodge, Rachel, McKeown, Astrid, Brown, Andrew P, Rukazenkov, Yuri, Ramalingam, Suresh S, Vansteenkiste, Johan

“…Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with…”
Get full text

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC by Tsuboi, Masahiro, Herbst, Roy S., John, Thomas, Kato, Terufumi, Majem, Margarita, Grohé, Christian, Wang, Jie, Goldman, Jonathan W., Lu, Shun, Su, Wu-Chou, de Marinis, Filippo, Shepherd, Frances A., Lee, Ki Hyeong, Le, Nhieu Thi, Dechaphunkul, Arunee, Kowalski, Dariusz, Poole, Lynne, Bolanos, Ana, Rukazenkov, Yuri, Wu, Yi-Long

“…Patients with resected, EGFR -mutated, stage IB to IIIA NSCLC were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. The 5-year overall…”
Get full text

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer by Soria, Jean-Charles, Ohe, Yuichiro, Vansteenkiste, Johan, Reungwetwattana, Thanyanan, Chewaskulyong, Busyamas, Lee, Ki Hyeong, Dechaphunkul, Arunee, Imamura, Fumio, Nogami, Naoyuki, Kurata, Takayasu, Okamoto, Isamu, Zhou, Caicun, Cho, Byoung Chul, Cheng, Ying, Cho, Eun Kyung, Voon, Pei Jye, Planchard, David, Su, Wu-Chou, Gray, Jhanelle E, Lee, Siow-Ming, Hodge, Rachel, Marotti, Marcelo, Rukazenkov, Yuri, Ramalingam, Suresh S

“…In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had…”
Get full text

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer by Gray, Jhanelle E, Okamoto, Isamu, Sriuranpong, Virote, Vansteenkiste, Johan, Imamura, Fumio, Lee, Jong Seok, Pang, Yong-Kek, Cobo, Manuel, Kasahara, Kazuo, Cheng, Ying, Nogami, Naoyuki, Cho, Eun Kyung, Su, Wu Chou, Zhang, Guili, Huang, Xiangning, Li-Sucholeiki, Xiaocheng, Lentrichia, Brian, Dearden, Simon, Jenkins, Suzanne, Saggese, Matilde, Rukazenkov, Yuri, Ramalingam, Suresh S

“…To assess the utility of the EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with -mutated ( m; Ex19del and/or…”
Get full text

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC by Planchard, David, Jänne, Pasi A, Cheng, Ying, Yang, James C-H, Yanagitani, Noriko, Kim, Sang-We, Sugawara, Shunichi, Yu, Yan, Fan, Yun, Geater, Sarayut L, Laktionov, Konstantin, Lee, Chee K, Valdiviezo, Natalia, Ahmed, Samreen, Maurel, Jean-Marc, Andrasina, Igor, Goldman, Jonathan, Ghiorghiu, Dana, Rukazenkov, Yuri, Todd, Alex, Kobayashi, Kunihiko

“…Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and T790M…”
Get full text

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses by Mok, Tony S K, Kim, Sang-We, Wu, Yi-Long, Nakagawa, Kazuhiko, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Shi, Xiaojin, Rukazenkov, Yuri, Haddad, Vincent, Thress, Kenneth S, Soria, Jean-Charles

“…Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study (IMPRESS) compared the continuation of gefitinib plus chemotherapy with…”
Get full text

Exposure-response modelling of osimertinib in patients with non-small cell lung cancer by Johnson, Martin, Lin, Yu-Wei, Schmidt, Henning, Sunnaker, Mikael, Van Maanen, Eline, Huang, Xiangning, Rukazenkov, Yuri, Tomkinson, Helen, Vishwanathan, Karthick

“…Osimertinib is a third-generation, irreversible, central nervous system-active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with…”
Get full text

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial by Di Leo, Angelo, Jerusalem, Guy, Petruzelka, Lubos, Torres, Roberto, Bondarenko, Igor N, Khasanov, Rustem, Verhoeven, Didier, Pedrini, José L, Smirnova, Iya, Lichinitser, Mikhail R, Pendergrass, Kelly, Malorni, Luca, Garnett, Sally, Rukazenkov, Yuri, Martin, Miguel

“…At the time of the initial analysis of overall survival (OS) for the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) randomized,…”
Get full text

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer by Planchard, David, Boyer, Michael J, Lee, Jong-Seok, Dechaphunkul, Arunee, Cheema, Parneet K, Takahashi, Toshiaki, Gray, Jhanelle E, Tiseo, Marcello, Ramalingam, Suresh S, Todd, Alexander, McKeown, Astrid, Rukazenkov, Yuri, Ohe, Yuichiro

“…In the phase III FLAURA study, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved…”
Get full text

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) by John, Tom, Grohe, Christian, Goldman, Jonathan W., Kato, Terufumi, Laktionov, Konstantin K., Bonanno, Laura, Tiseo, Marcello, Majem, Margarita, Domine, Manuel, Ahn, Myung-Ju, Perol, Maurice, Hartmaier, Ryan, Robichaux, Jacqulyne, Bhetariya, Preetida, Markovets, Aleksandra, Rukazenkov, Yuri, Muldoon, Caitlin, Herbst, Roy S., Tsuboi, Masahiro, Wu, Yi-Long

“…8005 Background: Osimertinib (osi) is a third-generation, central nervous system-active EGFR-TKI, that potently and selectively inhibits EGFR-TKI sensitizing…”
Get full text

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) by Herbst, Roy S., Tsuboi, Masahiro, John, Tom, Kato, Terufumi, Majem, Margarita, Grohé, Christian, Wang, Jie, Goldman, Jonathan W., Lu, Shun, Su, Wu-Chou, de Marinis, Filippo, Shepherd, Frances A., Lee, Ki Hyeong, Le, Nhieu, Dechaphunkul, Arunee, Kowalski, Dariusz M., Poole, Lynne, Stachowiak, Marta, Rukazenkov, Yuri, Wu, Yi-Long

“…LBA3 Background: Osimertinib is a third-generation, central nervous system (CNS) active EGFR-TKI, that potently and selectively inhibits EGFR-TKI sensitizing…”
Get full text

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA by Herbst, Roy S., Tsuboi, Masahiro, John, Thomas, Grohé, Christian, Majem, Margarita, Goldman, Jonathan Wade, Kim, Sang-We, Marmol, Dominika, Rukazenkov, Yuri, Wu, Yi-Long

“…Abstract only LBA5 Background: Osimertinib is a 3rd-generation, CNS-active, EGFR-TKI with superior efficacy to comparator EGFR-TKI (gefitinib/erlotinib) in…”
Get full text